LiDCO the cardiovascular monitoring company is today holding an Open Day for investors and analysts at St Thomas’ Hospital, London, from 2pm until 5pm. The purpose of this Open Day is to brief investors on LiDCO’s R&D strategy including details of the latest software Version 4.0 and the new research and clinical audit product LiDCOview.

The new software package, Version 4.0, in combination with the LiDCOview demonstrates how LiDCO’s technology has made a significant leap forward in graphical user interface development compared with the market’s current and older, non-PC based hemodynamic monitoring products.

Significant improvements to the new software package include:

• Improvements have been developed to allow the user to target and monitor specific oxygen delivery goals – the use of the LiDCOplus Monitor to maintain oxygen levels in high-risk surgery patients has already been demonstrated to reduce mean hospital stay by 12 days.



• New measurement for improved fluid management and improved graphical user interface – the LiDCO sensor now provides Intra Thoracic Blood Volume (“ITBV”). Correct fluid management of patients in surgery, trauma and intensive care locations improves cardiac performance and critically the oxygen delivery to vital organs which has been shown to reduce hospital bed stay. The ITBV has been reported* as being a much more sensitive guide to the fluid management of patients than the traditional invasive catheter based measurement of pulmonary artery wedge pressure.



• Improvements to the calibration consistency – calibration is now more automatic, simpler and includes an audit function that highlights if a calibration has occurred successfully or should be repeated. Accurate measurement of oxygen delivery is important, modest shortfall in oxygen delivery for extended periods of time leads to tissue and organ failure that is avoidable and if occurs has enormous clinical and financial implications.



• LiDCOview a Windows based software product that is designed to help clinical staff to view historical LiDCOplus files. In its simplest form the LiDCOview allows the re-creation of the monitor trend screen seen at the bedside. Particularly, difficult cases and their management strategy can then be discussed in clinical forums in order to pass on these experiences to other physicians and nurses.

* Source: O Goedje et al Chest 2000 Vol 118 PP 775-781

Presentations made at the LiDCO R&D open day will be downloadable from www.lidco.com on the 10 October & LiDCO’s interim results and investor presentation ‘LiDCO’s Interim Results - six months ended 31 July 2006 will be available from the LiDCO website on the 18 October 2006.

Notes to Editors

About LiDCO Group Plc
LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of minimally invasive, computer-based hemodynamic monitoring equipment and disposables used primarily for the management of critical care and cardiovascular risk hospital patients. Use of LiDCO’s technology has been shown to significantly reduce the complications (particularly infections) and costs associated with major surgery.  The technology was invented in the Department of Applied Physiology based at St Thomas’ Hospital, London.

The Company’s manufacturing facility is in London N1, UK and its products are:

• LiDCOplus and PulseCO monitors: computer-based platforms for displaying and management of a range of real-time, continuous hemodynamic parameters including cardiac output, oxygen delivery and fluid volume;
  
  
• LiDCO disposables: used in conjunction with the LiDCOplus Monitor to accurately determine cardiac output in a minimally-invasive manner.

Distribution Network:
The Company has now achieved registration of its products in 14 markets in Europe, together with the USA, Brazil and Japan.  It sells direct in the USA and UK, and elsewhere through a worldwide network of specialty critical care distributors.